de Boer B J, Lycklama a Nijeholt A A, Kleinjans H A
Universitair Medisch Centrum, Julius Centrum voor Huisartsgeneeskunde en Patiëntgebonden onderzoek, Utrecht.
Ned Tijdschr Geneeskd. 2001 Apr 21;145(16):783-7.
To determine the results of an auto-injection therapy with papaverine-phentolamine (using an auto-injection pen) prescribed by a GP or a urologist, in patients with erectile dysfunction.
Prospective, comparative, descriptive.
A total of 603 men with erectile dysfunction who were prescribed papaverine-phentolamine auto-injection by 59 GPs and 76 urologists participated in the study. The physician completed a questionnaire at the first visit and during the three follow-up visits (the last at 6 months) and the patient kept a diary and gave a satisfaction score on a nine-point scale.
The cause of the erectile dysfunction was most commonly psychogenic/mixed somatic-psychogenic in the GP group and most commonly vascular in the urologist group (p > 0.05). The somatic comorbidity was the same (70%), whereas the prevalence of psychological symptoms differed (GP group: 6%; urologist group: 7%; p < 0.001). Attendance at all of the follow-up examinations was 38% for the GP group and 17% for the urologist group. The mean starting dose in the GP group was 0.49 ml and in the urologist group 0.70 ml (p < 0.001). The mean end dose was the same (about 1 ml). The frequency of adverse reactions was 9%: haematoma (5%), prolonged erection (1.8%). During the course of the investigation, 38% of the patients (31% in the GP group; 40% in the urologist group) discontinued the treatment owing to a limited effect, adverse reactions, difficult administration or problems related to the partner. In both the GP and the urologist group, 72% of the patients and 77% of the partners were satisfied or very satisfied with the auto-injection pen treatment. The patient's mean satisfaction score was 7.2.
Whether the patient was treated by a GP or a urologist, the auto-injection therapy with papaverine-phentolamine for erectile dysfunction, using an auto-injection pen, was well tolerated and was highly appreciated by both the patients and their partners. Nevertheless one third of the patients discontinued the treatment prior to the end of the study. The mean end dose of the medication was the same in both groups.
确定由全科医生（GP）或泌尿科医生开具的使用注射笔进行的罂粟碱 - 酚妥拉明自动注射疗法对勃起功能障碍患者的治疗效果。
前瞻性、对比性、描述性研究。
共有603名患有勃起功能障碍的男性参与了该研究，他们由59名全科医生和76名泌尿科医生开具了罂粟碱 - 酚妥拉明自动注射治疗处方。医生在首次就诊时以及三次随访（最后一次随访在6个月时）时填写问卷，患者记录日记并给出9分制的满意度评分。
全科医生组勃起功能障碍的最常见原因是心理性/躯体 - 心理混合性，泌尿科医生组则最常见为血管性（p>0.05）。躯体合并症相同（70%），而心理症状的患病率不同（全科医生组：6%；泌尿科医生组：7%；p<0.001）。全科医生组所有随访检查的参与率为38%，泌尿科医生组为17%。全科医生组的平均起始剂量为0.49毫升，泌尿科医生组为0.70毫升（p<0.001）。平均最终剂量相同（约1毫升）。不良反应发生率为9%：血肿（5%）、勃起时间延长（1.8%）。在研究过程中，38%的患者（全科医生组为31%；泌尿科医生组为40%）因效果有限、不良反应、给药困难或与伴侣相关的问题而停止治疗。在全科医生组和泌尿科医生组中，分别有72%的患者和77%的伴侣对自动注射笔治疗感到满意或非常满意。患者的平均满意度评分为7.2。
无论患者由全科医生还是泌尿科医生治疗，使用注射笔进行的罂粟碱 - 酚妥拉明自动注射疗法治疗勃起功能障碍的耐受性良好，患者及其伴侣都给予高度评价。然而，三分之一的患者在研究结束前停止了治疗。两组药物的平均最终剂量相同。
Zotero 插件